Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-GI3: Ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment for metastatic colorectal cancer
CTR20260804Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Akeso, Inc.. Started Jun 2026; status: active.
02
Drugs
ivonescimab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20260804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260804.